![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhiW_NYEUIFtMSPdqdtb8IWUK5flTH-uGe4A_KKmxSTIZa6r_66sSE2syZyJo2Yw91pqtdrTMA_7Y0M4KbZCuRNOhbY10mxq5y7dCFgZTRLHTSd3Ce99mDRCzGAjUBhmPmoyDvDrihzFqM/s320/ed-garmen_spacecamp.png)
Though preliminary reports are from a company press release and have not been independently verified, news that the
COVID-19 candidate vaccine being developed and trialled by a partnership between the Mainz-based BioNTech and the US drug concern Pfizer vaccine exceeds effectiveness targets by a sizable margin (on par with the best childhood inoculations against measles) and suggests that protection is enduring is significant and hopeful. No serious safety concerns or side-effects were observed and the companies are already under contract to deliver tens of millions of doses.